文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克早期死亡相关的预后因素:系统评价与Meta分析

Prognostic factors associated with mortality in septic shock: a systematic review and meta-analysis.
PubMed 文献 · Lancet Respir Med · 2026-01-28
一句话结论该系统评价与Meta分析纳入95项研究、4 831 379例脓毒性休克患者,识别出与早期死亡独立相关的患者、就诊及治疗/生化因素,可辅助临床风险分层与治疗目标讨论。

该系统评价与Meta分析检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials(自建库至2025年8月13日),纳入评估脓毒性休克早期死亡(院内或至31天)预后因素的观察性研究和随机对照试验,排除儿童研究及尸检研究。最终纳入95项研究(90项观察性研究、5项随机对照试验),共4 831 379例患者,平均年龄64岁,男性58%、女性42%,早期院内死亡率33.2%(IQR 29.5-37.3)。与死亡率升高显著相关的因素包括年龄增长(每增加1岁校正OR 1.02)、Black race(1.23)、肝硬化(1.85)、恶性肿瘤(1.43)、Charlson合并症指数升高(每分1.22)、急性肾损伤(1.88)、APACHE II评分升高(每分1.10)、SAPS II评分升高(每分1.08)、SOFA评分升高(每分1.21)、有创机械通气(2.12)、使用去甲肾上腺素(3.60)及血清乳酸升高(每1 mmol/L 1.13)。作者认为识别这些预后因素有助于临床风险应用、治疗目标讨论及识别早期死亡风险最高和最低的患者亚组。

要点

  • 脓毒性休克患者早期院内死亡率为33.2%(IQR 29.5-37.3),合并肝硬化(校正OR 1.85,高确定性)和急性肾损伤(校正OR 1.88,高确定性)者死亡风险显著升高。
  • 治疗相关因素中,使用去甲肾上腺素与死亡率升高相关(校正OR 3.60,95%CI 2.73-4.74,高确定性),有创机械通气亦相关(校正OR 2.12,95%CI 1.00-4.51,中等确定性)。
  • 病情严重程度评分每升高1分均与死亡率升高独立相关:APACHE II校正OR 1.10、SAPS II校正OR 1.08、SOFA校正OR 1.21(均为高确定性)。
  • 血清乳酸每升高1 mmol/L与死亡率升高相关(校正OR 1.13,95%CI 1.01-1.26,高确定性)。
  • 作者认为这些预后因素可用于临床风险应用、治疗目标讨论,并识别早期死亡风险最高和最低的脓毒性休克患者亚组。

适用人群与场景

  • 纳入评估脓毒性休克预后因素与早期死亡(院内或至31天)的观察性研究和随机对照试验;排除儿童研究及尸检研究。
  • 共纳入4 831 379例脓毒性休克患者,平均年龄64岁,男性58%、女性42%。

研究设计与关键结果

  • 系统评价与Meta分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials(自建库至2025年8月13日),最终纳入95项研究(90项观察性研究、5项随机对照试验),共4 831 379例患者。
  • 早期院内死亡率为33.2%(IQR 29.5-37.3)。
  • 患者因素与死亡率升高显著相关:年龄每增加1岁校正OR 1.02(95%CI 1.01-1.02;I2=64%;中等确定性);Black race校正OR 1.23(95%CI 1.21-1.25;I2=0%;中等确定性);肝硬化校正OR 1.85(95%CI 1.64-2.08;I2=0%;高确定性);恶性肿瘤校正OR 1.43(95%CI 1.09-1.88;I2=91%;高确定性);Charlson合并症指数每增加1分校正OR 1.22(95%CI 1.19-1.25;I2=0%;高确定性)。
  • 就诊因素与死亡率升高显著相关:急性肾损伤校正OR 1.88(95%CI 1.32-2.68;I2=86%;高确定性);APACHE II评分每升高1分校正OR 1.10(95%CI 1.08-1.12;I2=60%;高确定性);SAPS II评分每升高1分校正OR 1.08(95%CI 1.06-1.09;I2=0%;高确定性);SOFA评分每升高1分校正OR 1.21(95%CI 1.15-1.28;I2=66%;高确定性)。
  • 治疗及生化因素与死亡率升高显著相关:有创机械通气校正OR 2.12(95%CI 1.00-4.51;I2=86%;中等确定性);使用去甲肾上腺素校正OR 3.60(95%CI 2.73-4.74;I2=0%;高确定性);血清乳酸每升高1 mmol/L校正OR 1.13(95%CI 1.01-1.26;I2=72%;高确定性)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入95项研究(90项观察性研究、5项随机对照试验),采用随机效应模型、通用逆方差法计算校正OR,p<0.05为显著,研究注册于Open Science Framework(OSF: 10.17605/OSF.IO/75H4G)。
  • 证据确定性:年龄、Black race、有创机械通气为中等确定性;肝硬化、恶性肿瘤、Charlson合并症指数、急性肾损伤、APACHE II、SAPS II、SOFA、去甲肾上腺素使用、血清乳酸为高确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为识别这些预后因素有助于临床风险应用、治疗目标讨论,并识别早期死亡风险最高和最低的脓毒性休克患者亚组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Septic shock is associated with high mortality rates ranging from 30% to 50%. In this systematic review and meta-analysis, we aimed to identify prognostic factors of early mortality in septic shock.

METHODS: A systematic review and meta-analysis of prognostic factors associated with early mortality in septic shock was performed. MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from database inception to Aug 13, 2025, were searched. All observational and randomised controlled trial studies that evaluated prognostic factors and early mortality (in-hospital or up to 31-days) in septic shock were included. Studies were excluded if they evaluated children or were post-mortem studies. Title and abstracts were reviewed by two independent reviewers. Summary data were extracted from published reports. The primary objective was to evaluate prognostic factors associated with mortality, reported as adjusted odds ratios (OR) using generic inverse variance method and random effects model and variables were significant if the p value was less than 0·05. This study was registered with Open Science Framework (OSF: 10.17605/OSF.IO/75H4G).

FINDINGS: Of 6814 records identified by our search, 1420 articles were assessed for full-text review, of these, 95 studies of 4 831 379 patients were included. Of 95 included studies, 90 (95%) were observational studies and five (5%) were randomised controlled trials. In 4 831 379 patients, the mean age was 64 years, 58% of participants were male, 42% were female, and early hospital mortality occurred in 1 606 384 patients (33·2% [IQR 29·5-37·3]). Patient factors significantly associated with increased mortality included increasing age (adjusted OR 1·02 per 1 year [95% CI 1·01-1·02; I2 =64%; moderate certainty), Black race (1·23 [1·21-1·25]; I2 =0%; moderate certainty), hepatic cirrhosis (1·85 [1·64-2·08]; I2 =0%; high certainty), malignancy (1·43 [1·09-1·88]; I2 =91%; high certainty), and increased Charlson comorbidity index (1·22 per point [1·19-1·25]; I2 =0%; high certainty). Presentation factors associated with increased mortality included acute kidney injury (1·88 [1·32-2·68]; I2 =86%; high certainty) and higher severity-of-illness scores, including Acute Physiology and Chronic Health Evaluation II score (1·10 per point increase [1·08-1·12]; I2 =60%; high certainty), Simplified Acute Physiology Score II (1·08 per point increase [1·06-1·09]; I2 =0%; high certainty), and Sequential Organ Failure Assessment (1·21 per point increase [1·15-1·28]; I2 =66%; high certainty). Treatment and biochemical factors associated with increased mortality included invasive mechanical ventilation (2·12 [1·00-4·51]; I2 =86%; moderate certainty), norepinephrine use (3·60 [2·73-4·74]; I2 =0%; high certainty), and elevated serum lactate (1·13 per 1 mmol/L [1·01-1·26]; I2 =72%; high certainty).

INTERPRETATION: This systematic review and meta-analysis identified prognostic factors associated with early mortality in septic shock. The identification of these prognostic factors could aid in clinical risk application, goals of care discussions, and identifying the subset of patients at highest and lowest risk of early mortality for patients with septic shock.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Jung RG, Gupta A, Stotts C, et al. Prognostic factors associated with mortality in septic shock: a systematic review and meta-analysis. Lancet Respir Med. 2026. PMID: 41619747. doi:10.1016/S2213-2600(25)00397-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。